This program is currently on indefinite hold due to changing NIH policies.
Amount available: $30,000 in direct costs for 1 year
Apply through the UCSF Resource Allocation Program (RAP) portal
The International Mentored Scientist Award seeks to provide a mentored career development opportunity in HIV research for international investigators affiliated with UCSF. Applicants for this award must indicate a UCSF-affiliated faculty research mentor(s) in HIV who will commit to guiding the applicant for the application process and throughout the duration of the proposed project. Project proposals should be geared toward the interests of the applicant (e.g., clinical, basic, implementation science and/or behavioral-epidemiological research) and focus on HIV research in the investigator’s home country.
Eligibility
Researchers (all levels), post-doctoral fellows, and trainees located at a UCSF-affiliated foreign institution who have not received an NIH R01- equivalent grant in HIV/AIDS are eligible. Please note that CFAR is not allowed to provide funding to any investigators who have received HIV-related R01 awards. More senior faculty members may apply only if they are newly entering the field of HIV research.
Designation of Mentor (Critical)
Mentoring is critical to the training component of the CFAR International Mentored Scientist awards. All International Mentored award applications require a faculty research mentor from UCSF or a UCSF-affiliated institution (https://cfar.ucsf.edu/about/partners). Applications without a mentor will be disqualified.
Applicants must identify their UCSF-affiliated mentors and arrange to receive mentor advice and guidance on the research portion of their application well before it is submitted (typically at least two months before the RAP deadline). CFAR is no longer available to assist with mentor identification.
Projects must be within NIH’s HIV/AIDS research high or medium priority areas. Projects in closely related areas (e.g. TB, HCV, drug use, etc.) must be clearly linked to HIV in order to be eligible for CFAR funding.
CFAR requests that applicants review the NIAID HIV Language Guide as they prepare their proposals so that they can follow best practices on language for communicating respectfully about HIV and related topics, including the use of person-first, non-stigmatizing language. Please contact us if you have any questions about this request.
The award amount is $30,000 in direct costs for one year.
For more detailed information about this RFA, please see the RAP Portal.
International Mentored Science Awardees
38 Awards
-
Perioperative Exposure to Blood and Body Fluids: Incidence, Causes and Attitudes in Uganda
Perioperative Exposure to Blood and Body Fluids: Incidence, Causes and Attitudes in Uganda
Abstract
Protection of operating theatre personnel from bloodborne pathogens has been neglected in Uganda. Nature, frequency, risk factors, and preventive measures for perioperative exposure of theatre personnel will be identified by conducting a 6 month cross-sectional study in Mulago Hospital, Uganda. Multiple logistic regression will analyze risk factors for exposure. Case exposure rate and cumulative risk of seroconversion of HIV will be calculated. Surveys of theatre personnel will assess knowledge, attitude, and practice for risks of perioperative bloodborne infections.
-
Perioperative Exposure to Blood and Body Fluids: Incidence, Causes and Attitudes in Uganda
Perioperative Exposure to Blood and Body Fluids: Incidence, Causes and Attitudes in Uganda
Abstract
Protection of operating theatre personnel from bloodborne pathogens has been neglected in Uganda. Nature, frequency, risk factors, and preventive measures for perioperative exposure of theatre personnel will be identified by conducting a 6 month cross-sectional study in Mulago Hospital, Uganda. Multiple logistic regression will analyze risk factors for exposure. Case exposure rate and cumulative risk of seroconversion of HIV will be calculated. Surveys of theatre personnel will assess knowledge, attitude, and practice for risks of perioperative bloodborne infections.
-
Family Planning Use Among Female Clients Attending The HIV/AIDS Clinic In Mbarara University Teaching Hospital
Family Planning Use Among Female Clients Attending The HIV/AIDS Clinic In Mbarara University Teaching Hospital
Abstract
The use of family planning has been shown to have strong potential to reduce new HIV infections due to unwanted fertility in Uganda. Most prevention of mother to child transmission PMTCT efforts to date have prioritized the provision of antiretroviral prophylaxis to HIV infected pregnant women, leaving voluntary contraception an underutilized approach despite evidence that preventing unintended pregnancies in the HIV infected women is an effective strategy for reducing HIV positive births and is cost effective.
-
Family Planning Use Among Female Clients Attending The HIV/AIDS Clinic In Mbarara University Teaching Hospital
Family Planning Use Among Female Clients Attending The HIV/AIDS Clinic In Mbarara University Teaching Hospital
Abstract
The use of family planning has been shown to have strong potential to reduce new HIV infections due to unwanted fertility in Uganda. Most prevention of mother to child transmission PMTCT efforts to date have prioritized the provision of antiretroviral prophylaxis to HIV infected pregnant women, leaving voluntary contraception an underutilized approach despite evidence that preventing unintended pregnancies in the HIV infected women is an effective strategy for reducing HIV positive births and is cost effective.
-
Mechanisms of CD4 T-cell death among HIV-infected, HAART-treated African adults displaying poor CD4 T-cell reconstitution despite effective viral suppression
Mechanisms of CD4 T-cell death among HIV-infected, HAART-treated African adults displaying poor CD4 T-cell reconstitution despite effective viral suppression
Abstract
Most HIV-infected subjects exhibit a progressive rise in CD4 T-cell counts after initiation of highly active antiretroviral therapy (HAART). However, a subset of individuals exhibit very poor CD4 T cell recovery despite effective control of viremia. Increased activation-induced programmed cell death of CD4 T cells has been proposed as a mechanism underlying poor immune recovery. We propose to perform a nested case control study utilizing a rural cohort of HIV-infected adults whose CD4 T-cell counts have remained low (<50 cell increase) despite HAART for at least six months.
-
Adaptation of a Male Partner Educational Intervention Tool for Vaginal Microbicide Trials
Adaptation of a Male Partner Educational Intervention Tool for Vaginal Microbicide Trials
Abstract
In Sub-Saharan Africa, high hypothetical acceptability of vaginal microbicide trials among women has often been dampened by low male partner support. Formative work recently carried out among women in Kisumu, Kenya indicate that despite a high willingness (80%) to participate in upcoming vaginal microbicide trials, more than a third of the interviewees either did not think their partners would support their trial participation or were unsure of his support.
-
Adaptation of a Male Partner Educational Intervention Tool for Vaginal Microbicide Trials
Adaptation of a Male Partner Educational Intervention Tool for Vaginal Microbicide Trials
Abstract
In Sub-Saharan Africa, high hypothetical acceptability of vaginal microbicide trials among women has often been dampened by low male partner support. Formative work recently carried out among women in Kisumu, Kenya indicate that despite a high willingness (80%) to participate in upcoming vaginal microbicide trials, more than a third of the interviewees either did not think their partners would support their trial participation or were unsure of his support.
-
A study to evaluate the acceptability and feasibility of providing integrated HIV and maternal and child health services thorough well child services in KwaZulu Natal, South Africa
A study to evaluate the acceptability and feasibility of providing integrated HIV and maternal and child health services thorough well child services in KwaZulu Natal, South Africa
Abstract
In the KwaZulu-Natal (KZN) province of South Africa (SA), where antenatal HIV prevalence is 39.5%, there has been substantial impact of programs to prevent mother-to-child transmission (PMTCT) of HIV.However, despite the recognized benefits of early ART initiation for HIV-infected infants and maternal health care, there is substantial loss to follow-up of HIV-infected mothers and their infants after delivery. Barriers to effective utilization of postnatal HIV care and treatment services include logistical factors, competing demands, and psychological factors such as fear of stigmatization.
-
A study to evaluate the acceptability and feasibility of providing integrated HIV and maternal and child health services thorough well child services in KwaZulu Natal, South Africa
A study to evaluate the acceptability and feasibility of providing integrated HIV and maternal and child health services thorough well child services in KwaZulu Natal, South Africa
Abstract
In the KwaZulu-Natal (KZN) province of South Africa (SA), where antenatal HIV prevalence is 39.5%, there has been substantial impact of programs to prevent mother-to-child transmission (PMTCT) of HIV.However, despite the recognized benefits of early ART initiation for HIV-infected infants and maternal health care, there is substantial loss to follow-up of HIV-infected mothers and their infants after delivery. Barriers to effective utilization of postnatal HIV care and treatment services include logistical factors, competing demands, and psychological factors such as fear of stigmatization.
-
Optimizing Nevirapine Dosing in Patients Co-infected with Tuberculosis and HIV in Harare, Zimbabwe
Optimizing Nevirapine Dosing in Patients Co-infected with Tuberculosis and HIV in Harare, Zimbabwe
Abstract
Nevirapine (NVP) is the primary antiretroviral (ART) available in Zimbabwe. However, its use as first line ART is complicated by interactions with rifampicin (RIF), the primary drug available for tuberculosis (TB). In some cases ART treatment is delayed or avoided in TB co-infected patients. Previous studies of the effect of RIF on NVP pharmacokinetic (PK) exposure has been inconclusive, failing to generate specific recommendations regarding co-treatment. Moreover, PK and safety data for NVP with RIF have not been generated in our population in Zimbabwe.